Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat in Relapsed/Refractory AML or ALL
NCT03110354Phase 1Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of valemetostat in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at Day 28 and Treatment-Emergent Adverse Events up to 4 years. Started Apr 2017; status: terminated.
02
Drugs
valemetostat
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03110354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110354.